25 recruiting, 23 completed, 11 not yet recruiting, 11 unknown. 34 Phase 2, 15 Not applicable, 14 Phase 1, 4 Phase 3, 2 Early Phase 1.
Follow Rectal Adenocarcinoma: new trials by email Literature Review of Rectal Adenocarcinoma trials Research Report on Rectal Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates High Rare Dose Rectal Brachytherapy Boost - Rectal Adenocarcinoma, Rectal Cancer | Phase 2 | Recruiting | University of Colorado, Denver | 44 | 2026-11-01 | 2026-09-02 |
| ctDNA-Informed Management of Early-Stage Rectal Cancer Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT) - Rectal Adenocarcinoma, Rectal Cancer | Phase 2 | Not yet recruiting | University of California, Davis | 200 | 2026-10-01 | 2026-08-05 |
| Use of a Novel Camera to Check the Bowel After Polyp or Tumour Removal LumenEye X1 digital rectoscope - Bowel Cancer, Polyp Rectal | Not yet recruiting | University of Edinburgh | 30 | 2026-10-01 | 2026-08-26 | |
| NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 2 | Not yet recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 100 | 2026-09-01 | 2026-08-14 |
| SCARLET - Italian proSpeCtionAl obseRvationaL multicEntre Study on Treatment for recTal pT1 Cancer Rectal Cancer, Rectal Adenocarcinoma | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 196 | 2026-09-01 | 2026-07-10 | |
| SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 3 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 204 | 2026-05-20 | 2026-07-01 |
| A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer Serplulimab, Oncolytic Virus H101, XELOX Chemotherapy - Rectal Neoplasms, Rectal Adenocarcinoma | Phase 2 | Not yet recruiting | Chongqing University Cancer Hospital | 20 | 2026-05-01 | 2026-04-22 |
| Family Communications After Genetic Testing Biospecimen Collection, Genetic Testing, Communication Intervention - Colon Adenocarcinoma, Colorectal Adenocarcinoma | Not applicable | Recruiting | Alliance for Clinical Trials in Oncology | 4186 | 2026-04-06 | 2026-10-02 |
| Neoadjuvant Radiotherapy vs Upfront Surgery in Locally Advanced Proximal Rectal Cancer radiotherapy, surgery - Rectal Adenocarcinoma | Not applicable | Recruiting | Istanbul University | 100 | 2026-04-06 | 2026-09-03 |
| Advanced Endoscopic Resections for Rectal Neoplasms Endoscopic submucosal dissection, Endoscopic intramuscular dissection - Rectal Cancer, Rectal Adenocarcinoma | Not yet recruiting | Jagiellonian University | 300 | 2026-03-01 | 2026-02-18 | |
| Reporting of Tumour Deposits in Colorectal Cancer by Radiology and Pathology No Intervention: Observational Cohort - Rectal Adenocarcinoma | Not yet recruiting | Imperial College London | 225 | 2026-02-01 | 2026-01-15 | |
| A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial) Short-course Radiotherapy, SCRT, Toripalimab - Rectal Adenocarcinoma, High-risk Locally Advanced | Phase 2 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 76 | 2026-01-01 | 2026-06-25 |
| Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. Trastuzumab-Deruxtecan (T-DXd), Capecitabine, Bevacizumab - Colorectal Cancer, Colorectal Adenocarcinoma | Phase 2 | Recruiting | Gruppo Oncologico del Nord-Ovest | 42 | 2025-10-20 | 2026-02-17 |
| Involve-site Radiotherapy Combined With Chemotherapy and Immunotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer Reduced-field short-course radiotherapy, Immunotherapy combined with chemotherapy, Standard short-course radiotherapy - Rectal Adenocarcinoma | Phase 2 | Not yet recruiting | Longhao Li | 60 | 2025-09-19 | 2025-09-15 |
| SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC PD-1 inhibitor based immunotherapy - Rectal Cancer, Rectal Adenocarcinoma | Phase 2 | Recruiting | Ruijin Hospital | 104 | 2025-09-05 | 2025-09-30 |
| A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) Calderasib, Oxaliplatin, Leucovorin/levofolinate calcium - Colon Adenocarcinoma, Rectal Adenocarcinoma | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 477 | 2025-07-16 | 2026-10-07 |
| FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery Balstilimab, Biospecimen Collection, Botensilimab - Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8 | Phase 2 | Recruiting | City of Hope Medical Center | 26 | 2025-05-20 | 2026-06-29 |
| SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 2 | Completed | Sixth Affiliated Hospital, Sun Yat-sen University | 49 | 2025-04-02 | 2026-08-04 |
| Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer Pucotenlimab, Bevacizumab, Oxaliplatin - Rectal Adenocarcinoma | Phase 2 | Not yet recruiting | Sir Run Run Shaw Hospital | 33 | 2025-04-01 | 2025-03-12 |
| A Phase ll Study of Neoadjuvant Short-course Radiotherapy Followed by Ivonescimab and Chemotherapy in pMMR/MSS Locally Advanced Rectal Cancer lvonescimab, CAPOX (oxaliplatin/capecitabine), radiotherapy - Rectal Adenocarcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 90 | 2025-04-01 | 2025-04-09 |
Showing 20 of 88. Sign in to see all of them.
Rectal Neoplasms (88) · Colonic Neoplasms (20) · Colorectal Neoplasms (9) · Adenocarcinoma (3) · Endometrial Neoplasms (2) · Low Anterior Resection Syndrome (2) · Microsatellite Instability (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Anastomotic Leak (1) · Anus Neoplasms (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1)
Digestive System Diseases (88) · Digestive System Neoplasms (88) · Gastrointestinal Diseases (88) · Gastrointestinal Neoplasms (88) · Neoplasms by Site (88) · Rectal Diseases (88) · Intestinal Diseases (87) · Intestinal Neoplasms (87) · Neoplasms (87) · Colorectal Neoplasms (79) · Colonic Diseases (23) · Pathological Conditions, Signs and Symptoms (10) · Pathologic Processes (9) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6)
Capecitabine (19) · Oxaliplatin (15) · Fluorouracil (13) · Radiotherapy (10) · Leucovorin (9) · Bevacizumab (8) · Surgical Procedures, Operative (7) · dehydroftorafur (7) · Radiation (6) · Radiotherapy, Intensity-Modulated (5) · Biopsy (4) · Cetuximab (4) · Drug Therapy (3) · Folfox protocol (3) · Irinotecan (3)
M.D. Anderson Cancer Center (5) · Sixth Affiliated Hospital, Sun Yat-sen University (5) · National Cancer Institute (NCI) (4) · Roswell Park Cancer Institute (3) · H. Lee Moffitt Cancer Center and Research Institute (2) · Memorial Sloan Kettering Cancer Center (2) · OHSU Knight Cancer Institute (2) · Providence Health & Services (2) · Royal Marsden NHS Foundation Trust (2) · Sir Run Run Shaw Hospital (2) · University of California, San Francisco (2) · University of Colorado, Denver (2) · University of Oulu (2) · Aalborg University Hospital (1) · Academic and Community Cancer Research United (1)
United States (43) · China (12) · France (8) · Italy (6) · United Kingdom (6) · Finland (5) · Germany (3) · Puerto Rico (3) · Spain (3) · Belgium (2) · Egypt (2) · India (2) · Poland (2) · South Korea (2) · Turkey (Türkiye) (2)
Andrea Cercek, MD (2) · Adel Kardosh, M.D.,Ph.D. (1) · Alexis Leal, MD (1) · Anass M Majbar (1) · Ankit Sarin, MD (1) · Ann Raldow (1) · Carrie Peterson, MD (1) · Charles D Lopez, MD, PhD (1) · Charles Kunos (1) · Christos Fountzilas (1) · Cristiano Spada, MD, PhD (1) · Cristina A Dragean, MD (1)
PMID 12297930, PMID 16165701, PMID 16583289, PMID 18452041, PMID 21825890, PMID 21940307, PMID 25849254, PMID 25926352, PMID 25952796, PMID 27369739, PMID 28712102, PMID 29732957, PMID 31262657, PMID 31660992, PMID 31779699, PMID 32818460, PMID 33109741, PMID 34196693, PMID 34244284, PMID 34446053, PMID 35146939, PMID 35325225, PMID 35660797, PMID 35728817, PMID 35892341, PMID 35952709, PMID 36748942, PMID 37222204, PMID 37369852, PMID 37478389, PMID 38506889, PMID 38697618, PMID 38877993, PMID 39196580, PMID 39761503, PMID 40293177, PMID 41563802, PMID 41781240, PMID 42018309
P30CA016056 (3), K07CA133187 (1), P30CA015083 (1), P30CA016059 (1), P30CA033572 (1), P30CA046934 (1), P30CA093373 (1), R21CA263539 (1), U10CA021115 (1), U10CA180820 (1), U10CA180868 (1), U10CA180888 (1), UM1CA186644 (1), UM1CA186688 (1), UM1CA186712 (1)